Tubers and tumors: rapamycin therapy for benign and malignant tumors.
about
Targeting signal transduction pathways to eliminate chemotherapeutic drug resistance and cancer stem cells.Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies.Genome-scale RNAi on living-cell microarrays identifies novel regulators of Drosophila melanogaster TORC1-S6K pathway signaling.Frontier of epilepsy research - mTOR signaling pathway.SDF-1/CXCL12 induces directional cell migration and spontaneous metastasis via a CXCR4/Gαi/mTORC1 axis.Differing effects of systemically administered rapamycin on consolidation and reconsolidation of context vs. cued fear memories.Recent developments in brain tumor predisposing syndromes.Yin Yang 1 deficiency in skeletal muscle protects against rapamycin-induced diabetic-like symptoms through activation of insulin/IGF signaling.Hyperphosphorylation of ribosomal protein S6 predicts unfavorable clinical survival in non-small cell lung cancerA liaison between mTOR signaling, ribosome biogenesis and cancerThe miR-126-VEGFR2 axis controls the innate response to pathogen-associated nucleic acids.GSK3 signalling in neural development.Everolimus tablets for patients with subependymal giant cell astrocytomaFusogenic pH sensitive liposomal formulation for rapamycin: improvement of antiproliferative effect.Prognostic significance and function of phosphorylated ribosomal protein S6 in esophageal squamous cell carcinoma.S6K1 determines the metabolic requirements for BCR-ABL survival.Nucleocytoplasmic localization of p70 S6K1, but not of its isoforms p85 and p31, is regulated by TSC2/mTOR.Pharmacological manipulation of the akt signaling pathway regulates myxoma virus replication and tropism in human cancer cells.PEComa of the colon resistant to sirolimus but responsive to doxorubicin/ifosfamide.New roles for Notch in tuberous sclerosis.The growing importance of mTORC1-S6K1 signaling in kidney.Sirolimus Ointment for Facial Angiofibromas in Individuals with Tuberous Sclerosis Complex.Ribosomal proteins: insight into molecular roles and functions in hepatocellular carcinoma.S6K inhibition renders cardiac protection against myocardial infarction through PDK1 phosphorylation of Akt.
P2860
Q33823577-E20C9B17-0128-441C-A331-34B403CE0EB7Q34536450-02DE124B-A51D-451A-BF19-DB43152DAC9DQ34605623-78FCF7A1-20E8-4B23-9916-1A7FA5A6BFA9Q35014198-9FBA1DA7-2A3A-4212-87EC-D41A13365319Q35576488-C1D09875-8EA8-4CCA-9B3A-E645D0188BBFQ35667946-520CB3B3-6630-48BE-9F55-81C402C4AFCEQ35860402-80FDF69E-518B-4B34-807C-F5713F861C3AQ35884554-82365AC6-6B10-4462-B318-E301E496DFB6Q36200159-C1B678AC-B061-483A-BD26-51B1B6F628DFQ36615429-C6991425-B3AC-4FA8-BABC-D81EE214D720Q37495470-DF05612F-8C9C-4555-8D6B-5A57DC38CA2DQ37774552-3700DEDF-44C2-49E7-A698-A4B0B2E3C775Q37909448-AEE7A177-81D2-4889-8D80-496E4AE8D676Q38985738-1811BAA7-7D68-42FA-A3E2-7B36B270D56CQ39274647-37F00B02-6692-4593-B169-EE62B1ABB267Q39385165-66092160-F453-4440-8CE6-8FBACEFC5BBEQ39538410-55554E1E-B23B-4AD6-9EEA-0510815BC192Q39610261-CCFEB7DA-9300-4D3D-9BFC-3A134FE5BB07Q41861277-01FFCB38-2319-4A14-8F15-5C36A84AA308Q42129355-90A805EB-BDB8-4AF4-B424-0B25E7AB5122Q45943478-7796053F-D0F5-4C46-B901-9B630950804AQ47139666-FAC93CF6-4C7E-4CFE-B0D6-1EBEA502B80AQ47748537-926470F9-3196-4EF6-A014-AA94418B2687Q54561835-DBD48C67-478B-46B5-A51D-A6F29E2EAF09
P2860
Tubers and tumors: rapamycin therapy for benign and malignant tumors.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Tubers and tumors: rapamycin therapy for benign and malignant tumors.
@en
Tubers and tumors: rapamycin therapy for benign and malignant tumors.
@nl
type
label
Tubers and tumors: rapamycin therapy for benign and malignant tumors.
@en
Tubers and tumors: rapamycin therapy for benign and malignant tumors.
@nl
prefLabel
Tubers and tumors: rapamycin therapy for benign and malignant tumors.
@en
Tubers and tumors: rapamycin therapy for benign and malignant tumors.
@nl
P1476
Tubers and tumors: rapamycin therapy for benign and malignant tumors.
@en
P2093
David R Plas
George Thomas
P304
P356
10.1016/J.CEB.2008.12.013
P577
2009-02-23T00:00:00Z